Mizuho Securities Raises Price Target to $36 Following Horizon Pharma's (HZNP) Announced Crealta Deal

National Health Partners (HPR) Enters ACTIMMUNE Phase 1 with Fox Chase Cancer Center

Horizon Pharma plc (NASDAQ: HZNP) announced that it, in collaboration with Fox Chase Cancer Center Temple Health, has initiated a Phase 1 clinical study to evaluate ACTIMMUNE (interferon gamma-1b) in combination with nivolumab in advanced solid tumors.

"We are eager to explore the safety and efficacy of ACTIMMUNE in combination with nivolumab in multiple, difficult-to-treat cancers that are often inoperable or have become unresponsive to standard therapies," said Jeffrey W. Sherman, M.D., FACP, executive vice president, research and development and chief medical officer, Horizon Pharma plc. "Through this study,... More

Notable Mergers and Acquisitions 12/11: (DOW)/(DD) (BABA) (HZNP) (APOL)

* DuPont (NYSE: DD) and The Dow Chemical Company (NYSE: DOW) announced that their boards of directors unanimously approved a definitive agreement under which the companies will combine in an all-stock merger of equals. The combined company will be named DowDuPont. The parties intend to subsequently pursue a separation of DowDuPont into three independent, publicly traded companies through tax-free spin-offs. This would occur as soon as feasible, which is expected to be 18-24 months following the closing of the merger, subject to regulatory and board approval.

The... More

Horizon Pharma (HZNP) will resume trading at 7:30am ET

Horizon Pharma (NASDAQ: HZNP) will resume trading at 7:30am EST.

Horizon Pharma (HZNP) to Acquire Crealta Holdings in $510M Cash Deal

Horizon Pharma plc (NASDAQ: HZNP) announced it has entered a definitive agreement to acquire Crealta Holdings LLC for $510 million in cash.

"The Crealta acquisition further diversifies our portfolio of medicines and aligns with our focus of acquiring value-enhancing, clinically differentiated, long-life medicines that treat orphan diseases," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "We have a proven track record of strong commercial execution and the ability to generate volume growth for clinically differentiated medicines. With our experienced rheumatology sales force and orphan expertise, we expect to... More

Horizon Pharma (HZNP) halted with news pending

Horizon Pharma (NASDAQ: HZNP) trading halted with news pending.